CSIMarket Company Name, Ticker, Suppliers, else..
 
Briacell Therapeutics Corp   (NASDAQ: BCTX)
 
Price: $3.6400 $0.04 1.111%
Day's High: $3.7690000534057617 Week Perf: 1.96 %
Day's Low: $ 3.61 30 Day Perf: 6.74 %
Volume (M): 57,400 52 Wk High: $ 14.68
Volume (M$): $ 0 52 Wk Avg: $5.95
Open: $3.68 52 Wk Low: $2.60



 Market Capitalization (Millions $) 26
 Shares Outstanding (Millions) 7
 Employees 22
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Business Description


BriaCell Therapeutics Corp is a clinical-stage biotechnology company that focuses on the development of targeted immunotherapy treatments for various types of cancer. The company's lead product candidate is Bria-IMT, which is a genetically engineered whole-cell therapy that targets breast cancer. Bria-IMT is designed to stimulate the patient's immune system to recognize and attack cancer cells. The company is currently conducting several clinical trials to evaluate the safety and efficacy of Bria-IMT in different cancer indications. BriaCell Therapeutics aims to provide innovative and personalized treatment options for patients with advanced breast cancer and potentially other types of solid tumors.


   Company Address: 235 15th Street, Suite 300 West Vancouver 0 BC
   Company Phone Number: 921-1810   Stock Exchange / Ticker: NASDAQ BCTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.83%    
JNJ   -3.42%    
LLY   -3.53%    
MRK   -5.04%    
PFE   -4.46%    
REGN   -7.13%    
• View Complete Report
   



Shares

BriaCell Takes Bold Steps Forward with 15:1 Share Consolidation and Breakthroughs in Personalized Breast Cancer Treatment,

Published Mon, Jan 27 2025 11:42 PM UTC

BriaCell Therapeutics Moves Forward with 15:1 Share Consolidation Amid Promising Breast Cancer DevelopmentsBriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSX: BCT), a forward-thinking clinical-stage biotechnology company, has announced the completion of a significant share consolidation aimed at enhancing its compliance with the listing requirements of the Nasdaq Capital ...
Clinical Study

BriaCells Bria-OTS Pioneering a Personalized Approach in Metastatic Breast Cancer Treatment,

Published Thu, Nov 21 2024 12:50 PM UTC

Revolutionary Steps in Metastatic Breast Cancer Treatment: BriaCell s Innovative Bria-OTS Study Begins In a significant breakthrough for metastatic breast cancer treatment, BriaCell Therapeutics Corp. a dynamic force in the biotech industry, has announced the dosing of the first patient in its groundbreaking Phase 1/2 study. This milestone marks the debut of Bria-OTS, BriaCe...
Clinical Study

BriaCell Therapeutics Charting a Bold Course in the Battle Against Metastatic Breast Cancer in Phase 3 Trials,

Published Tue, Oct 15 2024 11:51 AM UTC

Navigating New Frontiers in Metastatic Breast Cancer: BriaCell s Pioneering Phase 3 Clinical UpdateIn a transformative moment for oncological therapeutics, BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSX: BCT) has announced a significant clinical engagement update regarding its pivotal Phase 3 study involving Bria-IMT, an innovative immunotherapy designed for patients...
Announcement

BriaCell Takes Bold Step Towards Advanced Metastatic Breast Cancer Therapy with Innov...

Published Thu, May 30 2024 12:01 PM UTC

The fight against advanced metastatic breast cancer has taken a significant leap forward as BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), an innovative clinical-stage biotechnology company specializing in novel immunotherapies, commences patient enrollment in a pioneering Phase 1/2 clinical study. This trial seeks to evaluate the safety and efficacy of Bria-O...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1.13
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.35
Working Capital Ratio 7.07
Leverage Ratio (MRQ) 0.13
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -9.83 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.15 $
Book Value 3.23 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,408,017
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.